The Medical Advisor

Abstract The antiparasitic agents fenbendazole, mebendazole and ivermectin have recently emerged as promising candidates for adjunctive cancer therapy due to their multifaceted anticancer mechanisms and favorable safety profiles. Fenbendazole and mebendazole, benzimidazole derivatives, exert antitumor effects primarily through microtubule disruption and metabolic interference, inducing cell cycle arrest and apoptosis. Ivermectin, a macrocyclic lactone, complements these actions by inhibiting oncogenic signaling pathways such as STAT3, Wnt/β-catenin, and AKT/mTOR, while modulating immune responses. This review synthesizes updated clinical case reports demonstrating tumor regression in refractory malignancies—particularly triple-negative breast cancer, pancreatic, and colorectal cancers—alongside emerging mechanistic insights and pharmacokinetic considerations. Despite encouraging anecdotal outcomes, evidence remains preliminary, underscoring the urgent need for rigorous clinical trials ...